Download Full Version CCDS-O ACDIS Exam

In the outpatient setting, uncertain diagnoses described with terms such as “likely,” “probable,” “suspected,” or “rule out” generally arenotreported as established conditions for coding purposes. Instead, the encounter is coded to theconfirmed signs and symptomsdocumented and evaluated at that visit. Here, the provider’s assessment is “likely UTI,” with urine culture results still pending, so a definitive UTI diagnosis is not yet confirmed within the scenario. Likewise, the organism (E. coli) cannot be coded because it is only suspected and not confirmed until culture results are finalized. Outpatient CDI emphasizes aligning reportable diagnoses to what is clearly supported as present and addressed during the visit. The note explicitly identifies pain, urinary frequency, and fever—symptoms that drove evaluation and treatment (antipyretics and antibiotic initiation). Between the answer choices, “abdominal pain, fever, and urinary frequency” best represents the reportable conditions based on documented, evaluated symptoms without coding an uncertain infection diagnosis or an unconfirmed causative organism.

The documentation shows a patient with advanced COPD (GOLD stage 3) who now requires an increase in home oxygen to 3 liters, along with escalation of respiratory therapies (home nebulizers and systemic steroids). In outpatient CDI, an increased or ongoing home oxygen requirement is a strong clinical indicator that the provider may be managingchronic respiratory failure(or chronic hypoxemic respiratory failure), which is more clinically meaningful than simply documenting oxygen use as a status. “Oxygen dependence” is a status code and does not fully describe the underlying physiologic impairment driving the need for oxygen; chronic respiratory failure captures the severity and ongoing nature of the condition and better reflects risk, complexity, and medical necessity for durable oxygen therapy. Querying for pneumonia organism specificity is not as relevant in a follow-up visit unless pneumonia is still being actively treated and the organism is known. Querying COPD acuity (e.g., exacerbation) may be appropriate, but the most significant clarification prompted by increased home O2 is whether chronic respiratory failure is present and being managed.

A well-maintained problem list supports continuity of care by giving the care team an accurate, up-to-date clinical “snapshot” of active and relevant historical conditions that affect ongoing management, decision-making, and risk assessment. Outpatient CDI education emphasizes that the problem list should be curated—conditions should be current, clinically meaningful, and appropriately resolved or clarified (e.g., active vs history, controlled vs uncontrolled). Option A is incorrect because diagnoses are not removed based on an arbitrary time threshold; they are updated based on clinical status (resolved, inactive, erroneous, or no longer relevant). Option C is inaccurate because simply adding more diagnoses can introduce noise and increase the risk of outdated or incorrect conditions being propagated (“problem list bloat”), which can harm patient safety and lead to inaccurate coding. Option D is inaccurate because CDI professionals typicallydo notindependently update the problem list; rather, they support providers through compliant queries, education, and process improvements so the treating provider validates and maintains the record. Therefore, B best reflects outpatient documentation best practice.

In ambulatory CDI chart review, clinical indicators should align with assessment and management captured in the note (problem relevance and MEAT-style support: monitor, evaluate, assess/address, treat). This visit has two strong indicators that warrant medication evaluation. First, dyspnea plus a rapid 10-lb weight increase over two weeks is a classic signal of possible fluid overload in a patient with heart failure, making a loop diuretic such as Lasix clinically relevant to assess (effectiveness, adherence, dose changes, exacerbation risk, and whether HF is stable vs decompensated). Second, the A1c has worsened significantly (9.2 from 7.2), indicating inadequate glycemic control that should prompt review and adjustment of diabetes therapy; insulin such as NovoLog is directly tied to diabetes treatment escalation or optimization. The other medication pairs do not logically match the documented problems and indicators (e.g., appetite stimulant/anemia therapy, immunosuppressant, antidepressant/antihistamine). Therefore, NovoLog and Lasix best reflect what should be evaluated and addressed